Profile data is unavailable for this security.
About the company
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The Company's lead product is TPOXX, also known as tecovirimat and ST-246, an orally administered and intravenous (IV) formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the United States maintains a supply of TPOXX under Project BioShield. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. It uses third parties known as contract manufacturing organizations to procure commercial raw materials and supplies, and to manufacture TPOXX.
- Revenue in USD (TTM)157.02m
- Net income in USD79.26m
- Incorporated1995
- Employees45.00
- LocationSIGA Technologies Inc31 East 62Nd StreetNEW YORK 10065United StatesUSA
- Phone+1 (212) 672-9100
- Fax+1 (212) 697-3130
- Websitehttps://www.siga.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Heron Therapeutics Inc | 132.10m | -80.95m | 513.73m | 126.00 | -- | -- | -- | 3.89 | -0.6156 | -0.6156 | 0.9316 | -0.2245 | 0.6021 | 1.20 | 2.26 | 1,048,405.00 | -36.90 | -53.55 | -56.71 | -71.24 | 57.08 | 52.52 | -61.28 | -170.12 | 1.90 | -- | 1.29 | -- | 17.99 | 10.40 | 39.26 | -- | -29.97 | -- |
| Travere Therapeutics Inc | 155.72m | -415.73m | 514.63m | 380.00 | -- | 6.95 | -- | 3.30 | -5.32 | -2.00 | 2.04 | 0.9732 | 0.2116 | 1.57 | 7.04 | 409,800.00 | -56.49 | -36.95 | -71.19 | -44.77 | 94.34 | 95.92 | -266.96 | -165.79 | 2.75 | -- | 0.836 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
| Cabaletta Bio Inc | 0.00 | -76.87m | 515.11m | 118.00 | -- | 2.32 | -- | -- | -1.73 | -1.73 | 0.00 | 4.60 | 0.00 | -- | -- | 0.00 | -44.70 | -33.76 | -48.55 | -35.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.75 | -- | -- | -- |
| Olema Pharmaceuticals Inc | 0.00 | -99.34m | 517.39m | 75.00 | -- | 2.19 | -- | -- | -2.02 | -2.02 | 0.00 | 4.23 | 0.00 | -- | -- | 0.00 | -43.24 | -30.06 | -48.01 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
| Northwest Biotherapeutics Inc | 1.34m | -72.21m | 523.99m | 25.00 | -- | -- | -- | 392.21 | -0.0629 | -0.0629 | 0.0012 | -0.0447 | 0.0435 | -- | -- | 53,440.00 | -228.72 | -381.58 | -- | -- | -- | -- | -5,258.91 | -6,479.25 | -- | -10.49 | -- | -- | 14.80 | 36.21 | 38.71 | -- | 77.88 | -- |
| Y-mAbs Therapeutics Inc | 84.50m | -21.67m | 532.74m | 100.00 | -- | 5.37 | -- | 6.30 | -0.496 | -0.496 | 1.93 | 2.26 | 0.6481 | 1.31 | 4.30 | 844,990.00 | -16.62 | -44.23 | -19.95 | -50.45 | 86.53 | -- | -25.64 | -181.13 | 5.67 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
| GeneDx Holdings Corp | 221.85m | -135.02m | 536.88m | 1.00k | -- | 2.59 | -- | 2.42 | -5.25 | -5.25 | 8.60 | 7.93 | 0.4721 | 9.16 | 7.27 | 221,849.00 | -28.73 | -- | -35.07 | -- | 50.57 | 11.50 | -60.86 | -121.10 | 2.99 | -130.27 | 0.2015 | -- | -13.69 | 8.72 | 67.98 | -- | 7.77 | -- |
| Adaptive Biotechnologies Corp | 174.50m | -215.06m | 537.89m | 709.00 | -- | 1.96 | -- | 3.08 | -1.48 | -1.48 | 1.20 | 1.87 | 0.2472 | 4.52 | 4.78 | 246,124.10 | -30.48 | -19.69 | -34.73 | -22.06 | 57.06 | 67.18 | -123.29 | -122.27 | 4.35 | -- | 0.00 | -- | -8.11 | 25.06 | -12.52 | -- | 11.11 | -- |
| SIGA Technologies Inc | 157.02m | 79.26m | 542.66m | 45.00 | 6.96 | 3.29 | 6.79 | 3.46 | 1.10 | 1.10 | 2.20 | 2.32 | 0.7354 | 0.3631 | 10.32 | 3,489,424.00 | 37.12 | 22.34 | 47.49 | 27.56 | 87.71 | 88.65 | 50.48 | 41.14 | 2.19 | -- | 0.00 | 29.51 | 26.31 | -21.75 | 100.76 | -30.57 | -26.67 | -- |
| Entrada Therapeutics Inc | 162.87m | 23.49m | 544.87m | 160.00 | 25.73 | 2.01 | 20.34 | 3.35 | 0.6273 | 0.6273 | 4.79 | 8.02 | 0.3302 | -- | 3.89 | 1,024,359.00 | 4.76 | -- | 7.06 | -- | -- | -- | 14.42 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
| IGM Biosciences Inc | 2.11m | -236.92m | 545.38m | 216.00 | -- | 3.38 | -- | 259.09 | -4.31 | -4.31 | 0.0375 | 2.74 | 0.005 | -- | -- | 9,397.32 | -56.49 | -44.66 | -62.57 | -48.20 | -- | -- | -11,255.25 | -23,668.96 | -- | -- | 0.00 | -- | 99.25 | -- | -11.45 | -- | 73.48 | -- |
| Avid Bioservices Inc | 136.74m | -17.96m | 547.20m | 365.00 | -- | 3.04 | -- | 4.00 | -0.284 | -0.284 | 2.17 | 2.84 | 0.302 | 3.18 | 4.89 | 374,616.40 | -3.97 | 10.73 | -6.03 | 15.22 | 7.47 | 22.72 | -13.13 | 25.92 | 0.3097 | -5.04 | 0.4548 | 0.00 | 24.81 | 22.72 | -99.56 | -- | 82.90 | -- |
| enGene Holdings Inc | 0.00 | -106.80m | 554.35m | 33.00 | -- | 4.67 | -- | -- | -4.60 | -4.60 | 0.00 | 2.69 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1.37 | 0.2653 | -- | -- | -- | -260.87 | -- | -- | -- |
| Third Harmonic Bio Inc | 0.00 | -29.60m | 559.37m | 31.00 | -- | 2.09 | -- | -- | -0.7475 | -0.7475 | 0.00 | 6.55 | 0.00 | -- | -- | 0.00 | -10.53 | -- | -10.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.32 | -- | -- | -- |
| Kyverna Therapeutics Inc | 0.00 | -75.92m | 570.41m | 100.00 | -- | 1.58 | -- | -- | -1.73 | -1.73 | 0.00 | 8.37 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0045 | -- | -100.00 | -- | -108.93 | -- | -- | -- |
Data as of May 28 2024. Currency figures normalised to SIGA Technologies Inc's reporting currency: US Dollar USD
26.46%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.86m | 4.03% |
| First Wilshire Securities Management, Inc.as of 31 Mar 2024 | 2.65m | 3.73% |
| Van Lanschot Kempen Investment Management NVas of 31 Mar 2024 | 2.20m | 3.10% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 2.17m | 3.05% |
| AltraVue Capital LLCas of 31 Mar 2024 | 2.04m | 2.87% |
| Dimensional Fund Advisors LPas of 31 Mar 2024 | 1.69m | 2.37% |
| Federated MDTA LLCas of 31 Mar 2024 | 1.58m | 2.22% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 1.41m | 1.99% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.10m | 1.55% |
| Hotchkis & Wiley Capital Management LLCas of 31 Mar 2024 | 1.09m | 1.54% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
